Claims for Patent: RE38253

Summary for Patent: RE38253

Title:	Composition for contraception
Abstract:	A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from .[.0.25 to 0.30.]. .Iadd.2.5 to 3.0 .Iaddend.mg of drospirenone and .[.0.1 to 0.2.]. .Iadd.1 to 2 .Iaddend.mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
Inventor(s):	Spona; Jurgen (Vienna, AT), Dusterberg; Bernd (Berlin, DE), Ludicke; Frank (Geneva, CH)
Assignee:	Schering Aktiengesellschaft (Berlin, DE)
Application Number:	10/080,617
Patent Claims:	1. A combination product for oral contraception, comprising (a) 23 or 24 dosage units, each containing an estrogen selected from >2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, and b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days..]. .[. 2. A combination preparation for oral contraception according to claim 1, wherein the estrogen is ethinylestradiol..]..[. 3. A combination preparation of claim 2, wherein the gestagen is cyproterone acetate..]..[. 4. A combination preparation of claim 2, wherein the gestagen is drospirenone..]. 5. A combination preparation .[.according to claim 1.]. .Iadd.for oral contraception, comprising.Iaddend., .Iadd.(a) 23 or 24 dosage units, each containing an estrogen selected from .ltoreq.2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol: and a gestagen selected from 2.5 to 3.0 mg of drospirenone and 1 to 2 mg of cyproterone acetate, and b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days, .Iaddend. wherein the estrogen is present in a dose of 20 .mu.g of ethinylestradiol or an equivalent dose of 17.beta.-estradiol and the gestagen is present in a dose equivalent to 75 .mu.g of .[.gestadene.]. .Iadd.gestodene.Iaddend.. .[. 6. A combination preparation according to claim 1, which comprises 23 dosage units and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days or the menstrual cycle..]. 7. A combination preparation .[.according to claim 1.]. .Iadd.for oral contraception, comprising.Iaddend., .Iadd.(a) 23 or 24 dosage units, each containing an estrogen selected from >2.0 to 6.0 mg of 17.beta.-estradiol and 0.020 mg of ethinylestradiol: and a gestagen selected from 2.5 to 3.0 mg of drospirenone and 1 to 2 mg of cyproterone acetate, and (b) 5 or 4, respectively, active ingredient-free placebo pills or other indications to show that the daily administration of the 23 or 24 dosage units respectively, is to be followed by 5 or 4, respectively pill-free or placebo pill days, .Iaddend. which comprises 23 dosage units, each containing 20 .mu.g of ethinylestradiol and a dose of cyproterone acetate or drospirenone equivalent to 75 .mu.g of gestodene and 5 placebo pills or other indications to show that no dosage unit or a placebo pill is administered during the last 5 days of the menstrual cycle. .[. 8. A combination preparation of claim 1, wherein the estrogen is 17.beta.-estradiol..]..[. 9. A combination preparation of claim 8, wherein the gestagen is cyproterone acetate..]..[. 10. A combination preparation of claim 8, wherein the gestagen is drospirenone..].